Arthritis News and Research

Latest Arthritis News and Research

First Edition: June 22, 2012

Reporting for Kaiser Health News, Roni Caryn Rabin writes: "They say everything is bigger in Texas, and the problem of the uninsured is no exception. The Houston metropolitan area has one of the highest rates of uninsured people in America, and a health safety net imploding under the demands of too many people and too few resources.

22 Jun 2012

New melatonin analogues more efficient in inhibiting NOS activity in Parkinson's disease

University of Granada researchers have tested melatonin analogues in rats as it inhibits the enzyme nitric oxide synthase (NOS), which is involved in the development of conditions as inflammatory bowel disease, septic shock or rheumatoid arthritis, as well as in neurodegenerative conditions as Huntington's disease, Alzheimer's disease, Parkinson's disease and amyotrophic lateral sclerosis.

22 Jun 2012

FDA grants Orphan Drug Designation to Medgenics’ INFRADURE Biopump

Medgenics, Inc., the developer of Biopump, a novel technology for the sustained production and delivery of therapeutic proteins in patients using their own tissue, today announced that its INFRADURE Biopump has received Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) Office of Orphan Products Development (OOPD) for the treatment of hepatitis D.

21 Jun 2012

Omega-3 fatty acid supplements can reduce inflammation in overweight older adults

New research shows that omega-3 fatty acid supplements can lower inflammation in healthy, but overweight, middle-aged and older adults, suggesting that regular use of these supplements could help protect against and treat certain illnesses.

21 Jun 2012

Grunenthal to commercialize Horizon Pharma's DUEXIS in Latin America

Horizon Pharma, Inc. a biopharmaceutical company developing and commercializing innovative medicines to target unmet therapeutic needs in arthritis, pain and inflammatory diseases, today announced that it entered into an exclusive agreement with Grunenthal for the commercialization of DUEXIS in Latin America.

19 Jun 2012

AstraZeneca, Rigel enter global license agreement for R256 inhaled JAK inhibitor to treat chronic asthma

AstraZeneca and Rigel Pharmaceuticals Inc. today announced an exclusive worldwide license agreement for the global development and commercialization of R256, Rigel's inhaled JAK inhibitor shown to inhibit IL-13 and IL-4 signalling, which is being investigated as a treatment for moderate to severe chronic asthma. In preclinical research, R256 has been shown to reduce airway inflammation and improve lung function.

19 Jun 2012

Skin disease shares common inflammatory pathway with metabolic disorder

Psoriasis is an independent risk for Type 2 Diabetes, according to a new study by researchers with the Perelman School of Medicine at the University of Pennsylvania, with the greatest risk seen in patients with severe psoriasis.

19 Jun 2012

Mallinckrodt, Horizon enter co-promotion agreement for DUEXIS

Mallinckrodt, the Pharmaceuticals business of Covidien, today announced that it has entered into a co-promotion agreement with Horizon Pharma, Inc. to promote DUEXIS (ibuprofen and famotidine).

18 Jun 2012

Bristol-Myers Squibb, Scripps Research enter five-year collaboration

The Scripps Research Institute today announced it has entered into a five-year collaboration with Bristol-Myers Squibb Company focused on applying novel chemistry to drug discovery and synthesis.

16 Jun 2012

Patients with NK/T-cell lymphomas might benefit from treatment with JAK inhibitors

A substantial proportion of NK/T-cell lymphomas harbor Janus Kinase 3 gene mutations. Patients with these lymphomas might benefit from treatment with a Janus Kinase inhibitor according to a study published in Cancer Discovery, a journal of the American Association for Cancer Research.

16 Jun 2012

First inventory of microbial diversity in the world's oceans

The landmark publication this week of a "map" of the bacterial make-up of healthy humans has deep roots in an unexpected place: the ocean.

14 Jun 2012

Innovimmune receives $600,000 NIH grant to develop MIF inhibitors for RA

Specialty drug discovery company, Innovimmune Biotherapeutics, Inc. has been awarded a $600,000 Advanced Technology Small Business Innovation Research Grant from the National Institutes of Health (NIH).

14 Jun 2012

New analogues effective in inhibiting NOS activity in Parkinson models

14 Jun 2012

Multipronged approach relieves osteoarthritis pain

Using behavioral weight-management strategies alongside standard pain-coping skills training reduces the level of disability and pain experienced by overweight or obese individuals with osteoarthritis, US study results suggest.

13 Jun 2012

Georgia Institute of Technology launches HomeLab

Baby boomers have witnessed many technological innovations, and they expect technology to provide them with solutions to help maintain their independence for as long as possible. They are outfitting their homes with products to help them live healthy lifestyles, manage chronic conditions, remember to take medications and remain connected with their caregivers.

13 Jun 2012

Billions of specific gut bacteria may play a role in autoimmune diseases

The billions of bugs in our guts have a newfound role: regulating the immune system and related autoimmune diseases such as rheumatoid arthritis, according to researchers at Mayo Clinic and the University of Illinois at Urbana-Champaign.

13 Jun 2012

Scientists establish link between autoimmune diseases and nanoparticles

New groundbreaking research by scientists at Trinity College Dublin has found that exposure to nanoparticles can have a serious impact on health, linking it to rheumatoid arthritis and the development of other serious autoimmune diseases.

12 Jun 2012

Rheumatoid arthritis infection risk predicted by RABBIT

The RABBIT risk score can predict the likelihood of serious infection in rheumatoid arthritis patients using tumor necrosis factor-alpha inhibitors and disease-modifying antirheumatic drugs, research confirms.

11 Jun 2012

Incyte, Lilly announce 12-week results from baricitinib Phase IIb study on RA

Eli Lilly and Company and Incyte Corporation announced the presentation of 12-week results from a Phase IIb study of baricitinib, formerly LY3009104 (INCB28050), an orally available janus kinase (JAK) inhibitor, in patients with active rheumatoid arthritis.

11 Jun 2012

Lexicon presents six posters on LX4211 at ADA meeting

Lexicon Pharmaceuticals, Inc. will present six posters summarizing the mechanism of action and safety of LX4211, a dual inhibitor of sodium glucose transporters 1 and 2 (SGLT1 and SGLT2) currently in mid-stage development for type 2 diabetes, at the 72nd Scientific Sessions of the American Diabetes Association (ADA) in Philadelphia, Pennsylvania during the Saturday morning poster session on June 9, 2012.

10 Jun 2012